STAAR Surgical Company (STAA)
After hours:
| Previous close | 40.67 |
| Open | 40.97 |
| Bid | 40.02 x 100 |
| Ask | 40.15 x 100 |
| Day's range | 39.38 - 41.03 |
| 52-week range | 26.66 - 55.38 |
| Volume | |
| Avg. volume | 570,495 |
| Market cap | 1.969B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 129.26 |
| EPS (TTM) | 0.31 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.59 |
Investor's Business DailyStaar Surgical Stock Earns RS Rating Upgrade
Staar Surgical shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 87.
ZacksStaar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Business WireSTAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
LAKE FOREST, Calif., June 05, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida.
